These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 25368026)

  • 1. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
    Bauersachs J; Jaisser F; Toto R
    Hypertension; 2015 Feb; 65(2):257-63. PubMed ID: 25368026
    [No Abstract]   [Full Text] [Related]  

  • 2. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
    Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
    Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Roll of aldosterone in pathogenesis of kidney disorders].
    Kitamura K; Tomita K
    Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1428-34. PubMed ID: 16097603
    [No Abstract]   [Full Text] [Related]  

  • 4. Vascular actions of aldosterone.
    Briet M; Schiffrin EL
    J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a new dawn for selective mineralocorticoid receptor antagonism?
    Luther JM
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):456-61. PubMed ID: 24992570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone and its blockade: a cardiovascular and renal perspective.
    Lahera V; Cachofeiro V; Balfagon G; Rodicio JL
    ScientificWorldJournal; 2006 Apr; 6():413-24. PubMed ID: 16604252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone in heart and kidney diseases.
    Rentoukas EI; Lazaros GA; Zirogiannis PN
    Hellenic J Cardiol; 2005; 46(6):408-19. PubMed ID: 16422128
    [No Abstract]   [Full Text] [Related]  

  • 8. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoids and 11β-hydroxysteroid dehydrogenases: mechanisms for hypertension.
    Hunter RW; Bailey MA
    Curr Opin Pharmacol; 2015 Apr; 21():105-14. PubMed ID: 25666420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mineralocorticoid receptor: an update].
    Nagase M
    Nihon Rinsho; 2012 Sep; 70(9):1504-9. PubMed ID: 23012795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconsidering the roles of the mineralocorticoid receptor.
    Funder JW
    Hypertension; 2009 Feb; 53(2):286-90. PubMed ID: 19139379
    [No Abstract]   [Full Text] [Related]  

  • 12. Aldosterone-induced fibrosis in the kidney: questions and controversies.
    Brem AS; Morris DJ; Gong R
    Am J Kidney Dis; 2011 Sep; 58(3):471-9. PubMed ID: 21705125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of agents that affect aldosterone action.
    Tamargo J; Solini A; Ruilope LM
    Semin Nephrol; 2014 May; 34(3):285-306. PubMed ID: 25016400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation.
    Young MJ
    Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):174-80. PubMed ID: 18277151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
    Galuppo P; Bauersachs J
    Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.
    Rafiq K; Hitomi H; Nakano D; Nishiyama A
    J Pharmacol Sci; 2011; 115(1):1-7. PubMed ID: 21186336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology.
    Jaisser F; Farman N
    Pharmacol Rev; 2016 Jan; 68(1):49-75. PubMed ID: 26668301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.
    Brem AS; Gong R
    Clin Sci (Lond); 2015 May; 128(9):527-35. PubMed ID: 25671776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor--Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats.
    Kawarazaki H; Ando K; Shibata S; Muraoka K; Fujita M; Kawarasaki C; Fujita T
    J Hypertens; 2012 Oct; 30(10):1977-85. PubMed ID: 22914542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
    Tatsumi T; Matsubara H
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():524-9. PubMed ID: 16897886
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.